Project acronym 2G-CSAFE
Project Combustion of Sustainable Alternative Fuels for Engines used in aeronautics and automotives
Researcher (PI) Philippe Dagaut
Host Institution (HI) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS
Call Details Advanced Grant (AdG), PE8, ERC-2011-ADG_20110209
Summary This project aims at promoting sustainable combustion technologies for transport via validation of advanced combustion kinetic models obtained using sophisticated new laboratory experiments, engines, and theoretical computations, breaking through the current frontier of knowledge. It will focus on the unexplored kinetics of ignition and combustion of 2nd generation (2G) biofuels and blends with conventional fuels, which should provide energy safety and sustainability to Europe. The motivation is that no accurate kinetic models are available for the ignition, oxidation and combustion of 2G-biofuels, and improved ignition control is needed for new compression ignition engines. Crucial information is missing: data from well characterised experiments on combustion-generated pollutants and data on key-intermediates for fuels ignition in new engines.
To provide that knowledge new well-instrumented complementary experiments and kinetic modelling will be used. Measurements of key-intermediates, stables species, and pollutants will be performed. New ignition control strategies will be designed, opening new technological horizons. Kinetic modelling will be used for rationalising the results. Due to the complexity of 2G-biofuels and their unusual composition, innovative surrogates will be designed. Kinetic models for surrogate fuels will be generalised for extension to other compounds. The experimental results, together with ab-initio and detailed modelling, will serve to characterise the kinetics of ignition, combustion, and pollutants formation of fuels including 2G biofuels, and provide relevant data and models.
This research is risky because this is (i) the 1st effort to measure radicals by reactor/CRDS coupling, (ii) the 1st effort to use a μ-channel reactor to build ignition databases for conventional and bio-fuels, (iii) the 1st effort to design and use controlled generation and injection of reactive species to control ignition/combustion in compression ignition engines
Summary
This project aims at promoting sustainable combustion technologies for transport via validation of advanced combustion kinetic models obtained using sophisticated new laboratory experiments, engines, and theoretical computations, breaking through the current frontier of knowledge. It will focus on the unexplored kinetics of ignition and combustion of 2nd generation (2G) biofuels and blends with conventional fuels, which should provide energy safety and sustainability to Europe. The motivation is that no accurate kinetic models are available for the ignition, oxidation and combustion of 2G-biofuels, and improved ignition control is needed for new compression ignition engines. Crucial information is missing: data from well characterised experiments on combustion-generated pollutants and data on key-intermediates for fuels ignition in new engines.
To provide that knowledge new well-instrumented complementary experiments and kinetic modelling will be used. Measurements of key-intermediates, stables species, and pollutants will be performed. New ignition control strategies will be designed, opening new technological horizons. Kinetic modelling will be used for rationalising the results. Due to the complexity of 2G-biofuels and their unusual composition, innovative surrogates will be designed. Kinetic models for surrogate fuels will be generalised for extension to other compounds. The experimental results, together with ab-initio and detailed modelling, will serve to characterise the kinetics of ignition, combustion, and pollutants formation of fuels including 2G biofuels, and provide relevant data and models.
This research is risky because this is (i) the 1st effort to measure radicals by reactor/CRDS coupling, (ii) the 1st effort to use a μ-channel reactor to build ignition databases for conventional and bio-fuels, (iii) the 1st effort to design and use controlled generation and injection of reactive species to control ignition/combustion in compression ignition engines
Max ERC Funding
2 498 450 €
Duration
Start date: 2011-12-01, End date: 2016-11-30
Project acronym 3D-E
Project 3D Engineered Environments for Regenerative Medicine
Researcher (PI) Ruth Elizabeth Cameron
Host Institution (HI) THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Call Details Advanced Grant (AdG), PE8, ERC-2012-ADG_20120216
Summary "This proposal develops a unified, underpinning technology to create novel, complex and biomimetic 3D environments for the control of tissue growth. As director of Cambridge Centre for Medical Materials, I have recently been approached by medical colleagues to help to solve important problems in the separate therapeutic areas of breast cancer, cardiac disease and blood disorders. In each case, the solution lies in complex 3D engineered environments for cell culture. These colleagues make it clear that existing 3D scaffolds fail to provide the required complex orientational and spatial anisotropy, and are limited in their ability to impart appropriate biochemical and mechanical cues.
I have a strong track record in this area. A particular success has been the use of a freeze drying technology to make collagen based porous implants for the cartilage-bone interface in the knee, which has now been commercialised. The novelty of this proposal lies in the broadening of the established scientific base of this technology to enable biomacromolecular structures with:
(A) controlled and complex pore orientation to mimic many normal multi-oriented tissue structures
(B) compositional and positional control to match varying local biochemical environments,
(C) the attachment of novel peptides designed to control cell behaviour, and
(D) mechanical control at both a local and macroscopic level to provide mechanical cues for cells.
These will be complemented by the development of
(E) robust characterisation methodologies for the structures created.
These advances will then be employed in each of the medical areas above.
This approach is highly interdisciplinary. Existing working relationships with experts in each medical field will guarantee expertise and licensed facilities in the required biological disciplines. Funds for this proposal would therefore establish a rich hub of mutually beneficial research and opportunities for cross-disciplinary sharing of expertise."
Summary
"This proposal develops a unified, underpinning technology to create novel, complex and biomimetic 3D environments for the control of tissue growth. As director of Cambridge Centre for Medical Materials, I have recently been approached by medical colleagues to help to solve important problems in the separate therapeutic areas of breast cancer, cardiac disease and blood disorders. In each case, the solution lies in complex 3D engineered environments for cell culture. These colleagues make it clear that existing 3D scaffolds fail to provide the required complex orientational and spatial anisotropy, and are limited in their ability to impart appropriate biochemical and mechanical cues.
I have a strong track record in this area. A particular success has been the use of a freeze drying technology to make collagen based porous implants for the cartilage-bone interface in the knee, which has now been commercialised. The novelty of this proposal lies in the broadening of the established scientific base of this technology to enable biomacromolecular structures with:
(A) controlled and complex pore orientation to mimic many normal multi-oriented tissue structures
(B) compositional and positional control to match varying local biochemical environments,
(C) the attachment of novel peptides designed to control cell behaviour, and
(D) mechanical control at both a local and macroscopic level to provide mechanical cues for cells.
These will be complemented by the development of
(E) robust characterisation methodologies for the structures created.
These advances will then be employed in each of the medical areas above.
This approach is highly interdisciplinary. Existing working relationships with experts in each medical field will guarantee expertise and licensed facilities in the required biological disciplines. Funds for this proposal would therefore establish a rich hub of mutually beneficial research and opportunities for cross-disciplinary sharing of expertise."
Max ERC Funding
2 486 267 €
Duration
Start date: 2013-04-01, End date: 2018-03-31
Project acronym APRA
Project Active Polymers for Renewable Functional Actuators
Researcher (PI) Eugene TERENTJEV
Host Institution (HI) THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
Call Details Advanced Grant (AdG), PE8, ERC-2017-ADG
Summary The idea of mechanical actuator based on intrinsic material properties of liquid-crystalline elastomers (rather than complex engineering of interacting components) has been understood for 20+ years. The remarkable characteristics of LCE actuation (fully reversible action; large-amplitude, with a stroke of 5%-300%; stress-strain-speed response almost exactly matching the human muscle) make it highly attractive in biomedical engineering, robotics, smart textiles, and other fields. Yet, there is a profound difficulty (bottleneck), which remains the reason why this concept has not found its way into any practical devices & applications. LCE actuation requires alignment (monodomain structure) of the local anisotropy in the permanently crosslinked polymer network - which has been impossible to achieve in any useful large-scale configuration except the flat film, due to the unavoidable restrictions of two competing processes: orientational alignment and network crosslinking.
Recently, we made a breakthrough, developing LCE vitrimers (polymer networks covalently crosslinked by a bond-exchange reaction). Vitrimers are much more stable than other transient elastomer networks, allow easy thermal re-moulding (making the material fully renewable), and permit molding of complex shapes with intricate local alignment (which are impossible in traditional elastomers). This project will bridge from the concept to technology, tuning the material design for robust nematic LCE vitrimers, imparting photo-actuation capacity with a controlled wavelength, and finally utilising them in practical-engineering actuator applications where the reversible mechanical action is stimulated by light, solvent exposure, or more traditionally - heat. These applications include (but not limited to): continuous spinning light-driven motor, tactile dynamic Braille display, capillary pump and toggle flow switch for microfuidics, active textile fibre, and heliotracking filament that always points at the Sun.
Summary
The idea of mechanical actuator based on intrinsic material properties of liquid-crystalline elastomers (rather than complex engineering of interacting components) has been understood for 20+ years. The remarkable characteristics of LCE actuation (fully reversible action; large-amplitude, with a stroke of 5%-300%; stress-strain-speed response almost exactly matching the human muscle) make it highly attractive in biomedical engineering, robotics, smart textiles, and other fields. Yet, there is a profound difficulty (bottleneck), which remains the reason why this concept has not found its way into any practical devices & applications. LCE actuation requires alignment (monodomain structure) of the local anisotropy in the permanently crosslinked polymer network - which has been impossible to achieve in any useful large-scale configuration except the flat film, due to the unavoidable restrictions of two competing processes: orientational alignment and network crosslinking.
Recently, we made a breakthrough, developing LCE vitrimers (polymer networks covalently crosslinked by a bond-exchange reaction). Vitrimers are much more stable than other transient elastomer networks, allow easy thermal re-moulding (making the material fully renewable), and permit molding of complex shapes with intricate local alignment (which are impossible in traditional elastomers). This project will bridge from the concept to technology, tuning the material design for robust nematic LCE vitrimers, imparting photo-actuation capacity with a controlled wavelength, and finally utilising them in practical-engineering actuator applications where the reversible mechanical action is stimulated by light, solvent exposure, or more traditionally - heat. These applications include (but not limited to): continuous spinning light-driven motor, tactile dynamic Braille display, capillary pump and toggle flow switch for microfuidics, active textile fibre, and heliotracking filament that always points at the Sun.
Max ERC Funding
2 012 136 €
Duration
Start date: 2018-10-01, End date: 2023-09-30
Project acronym ARMOS
Project Advanced multifunctional Reactors for green Mobility and Solar fuels
Researcher (PI) Athanasios Konstandopoulos
Host Institution (HI) ETHNIKO KENTRO EREVNAS KAI TECHNOLOGIKIS ANAPTYXIS
Call Details Advanced Grant (AdG), PE8, ERC-2010-AdG_20100224
Summary Green Mobility requires an integrated approach to the chain fuel/engine/emissions. The present project aims at ground breaking advances in the area of Green Mobility by (a) enabling the production of affordable, carbon-neutral, clean, solar fuels using exclusively renewable/recyclable raw materials, namely solar energy, water and captured Carbon Dioxide from combustion power plants (b) developing a highly compact, multifunctional reactor, able to eliminate gaseous and particulate emissions from the exhaust of engines operated on such clean fuels.
The overall research approach will be based on material science, engineering and simulation technology developed by the PI over the past 20 years in the area of Diesel Emission Control Reactors, which will be further extended and cross-fertilized in the area of Solar Thermochemical Reactors, an emerging discipline of high importance for sustainable development, where the PI’s research group has already made significant contributions, and received the 2006 European Commission’s Descartes Prize for the development of the first ever solar reactor, holding the potential to produce on a large scale, pure renewable Hydrogen from the thermochemical splitting of water, also known as the HYDROSOL technology.
Summary
Green Mobility requires an integrated approach to the chain fuel/engine/emissions. The present project aims at ground breaking advances in the area of Green Mobility by (a) enabling the production of affordable, carbon-neutral, clean, solar fuels using exclusively renewable/recyclable raw materials, namely solar energy, water and captured Carbon Dioxide from combustion power plants (b) developing a highly compact, multifunctional reactor, able to eliminate gaseous and particulate emissions from the exhaust of engines operated on such clean fuels.
The overall research approach will be based on material science, engineering and simulation technology developed by the PI over the past 20 years in the area of Diesel Emission Control Reactors, which will be further extended and cross-fertilized in the area of Solar Thermochemical Reactors, an emerging discipline of high importance for sustainable development, where the PI’s research group has already made significant contributions, and received the 2006 European Commission’s Descartes Prize for the development of the first ever solar reactor, holding the potential to produce on a large scale, pure renewable Hydrogen from the thermochemical splitting of water, also known as the HYDROSOL technology.
Max ERC Funding
1 750 000 €
Duration
Start date: 2011-02-01, End date: 2017-01-31
Project acronym ATHENE
Project Designing new technical wastewater treatment solutions targeted for organic micropollutant biodegradation, by understanding enzymatic pathways and assessing detoxification
Researcher (PI) Thomas Ternes
Host Institution (HI) Bundesanstalt fuer Gewaesserkunde
Call Details Advanced Grant (AdG), PE8, ERC-2010-AdG_20100224
Summary The identification of degradation pathways relevant for organic micropollutants in biological wastewater treatment processes is currently a major gap, preventing a profound evaluation of the capability of biological wastewater treatment. By elucidating the responsible enzymatic reactions of mixed microbial populations this project will cover this gap and thereby allow finding technical solutions that harness the true potential of biological processes for an enhanced biodegradation and detoxification. Due to the multi-disciplinary approach Athene will have impacts on the fields of biological wastewater treatment, analytical and environmental chemistry, environmental microbiology, water and (eco)toxicity. The multi-disciplinary approach of the project requires the involvement of a co-investigator experienced in process engineering and microbiology in wastewater treatment. Athene will go far beyond state-of-the-art in the following fields: a) efficiency in chemical analysis and structure identification of transformation products at environmental relevant concentrations; b) identification of enzymatic pathways relevant for micropollutant degradation in biological wastewater treatment; c) designing innovative technical solutions to maximize biodegradation; d) map and model relevant enzymatic pathways for environmental concentrations. Furthermore, designing biological wastewater treatment processes by understanding enzymatic pathways relevant for organic micropollutants removal represents a paradigm shift for municipal wastewater treatment. In the context of the actual scientific discussion about the relevance of trace organics in the aquatic environment and in drinking water, this topic is deemed as highly innovative: for its potential of proposing new technical options as well as for the gain in understanding compound persistency. Finally enzymatic reactions as well as the treatment schemes will be assessed for there capability to reduce toxiciological effects.
Summary
The identification of degradation pathways relevant for organic micropollutants in biological wastewater treatment processes is currently a major gap, preventing a profound evaluation of the capability of biological wastewater treatment. By elucidating the responsible enzymatic reactions of mixed microbial populations this project will cover this gap and thereby allow finding technical solutions that harness the true potential of biological processes for an enhanced biodegradation and detoxification. Due to the multi-disciplinary approach Athene will have impacts on the fields of biological wastewater treatment, analytical and environmental chemistry, environmental microbiology, water and (eco)toxicity. The multi-disciplinary approach of the project requires the involvement of a co-investigator experienced in process engineering and microbiology in wastewater treatment. Athene will go far beyond state-of-the-art in the following fields: a) efficiency in chemical analysis and structure identification of transformation products at environmental relevant concentrations; b) identification of enzymatic pathways relevant for micropollutant degradation in biological wastewater treatment; c) designing innovative technical solutions to maximize biodegradation; d) map and model relevant enzymatic pathways for environmental concentrations. Furthermore, designing biological wastewater treatment processes by understanding enzymatic pathways relevant for organic micropollutants removal represents a paradigm shift for municipal wastewater treatment. In the context of the actual scientific discussion about the relevance of trace organics in the aquatic environment and in drinking water, this topic is deemed as highly innovative: for its potential of proposing new technical options as well as for the gain in understanding compound persistency. Finally enzymatic reactions as well as the treatment schemes will be assessed for there capability to reduce toxiciological effects.
Max ERC Funding
3 473 400 €
Duration
Start date: 2011-04-01, End date: 2017-03-31
Project acronym ATLAS
Project Bioengineered autonomous cell-biomaterials devices for generating humanised micro-tissues for regenerative medicine
Researcher (PI) João Felipe Colardelle da Luz Mano
Host Institution (HI) UNIVERSIDADE DE AVEIRO
Call Details Advanced Grant (AdG), PE8, ERC-2014-ADG
Summary New generations of devices for tissue engineering (TE) should rationalize better the physical and biochemical cues operating in tandem during native regeneration, in particular at the scale/organizational-level of the stem cell niche. The understanding and the deconstruction of these factors (e.g. multiple cell types exchanging both paracrine and direct signals, structural and chemical arrangement of the extra-cellular matrix, mechanical signals…) should be then incorporated into the design of truly biomimetic biomaterials. ATLAS proposes rather unique toolboxes combining smart biomaterials and cells for the ground-breaking advances of engineering fully time-self-regulated complex 2D and 3D devices, able to adjust the cascade of processes leading to faster high-quality new tissue formation with minimum pre-processing of cells. Versatile biomaterials based on marine-origin macromolecules will be used, namely in the supramolecular assembly of instructive multilayers as nanostratified building-blocks for engineer such structures. The backbone of these biopolymers will be equipped with a variety of (bio)chemical elements permitting: post-processing chemistry and micro-patterning, specific/non-specific cell attachment, and cell-controlled degradation. Aiming at being applied in bone TE, ATLAS will integrate cells from different units of tissue physiology, namely bone and hematopoietic basic elements and consider the interactions between the immune and skeletal systems. These ingredients will permit to architect innovative films with high-level dialogue control with cells, but in particular sophisticated quasi-closed 3D capsules able to compartmentalise such components in a “globe-like” organization, providing local and long-range order for in vitro microtissue development and function. Such hybrid devices could be used in more generalised front-edge applications, including as disease models for drug discovery or test new therapies in vitro.
Summary
New generations of devices for tissue engineering (TE) should rationalize better the physical and biochemical cues operating in tandem during native regeneration, in particular at the scale/organizational-level of the stem cell niche. The understanding and the deconstruction of these factors (e.g. multiple cell types exchanging both paracrine and direct signals, structural and chemical arrangement of the extra-cellular matrix, mechanical signals…) should be then incorporated into the design of truly biomimetic biomaterials. ATLAS proposes rather unique toolboxes combining smart biomaterials and cells for the ground-breaking advances of engineering fully time-self-regulated complex 2D and 3D devices, able to adjust the cascade of processes leading to faster high-quality new tissue formation with minimum pre-processing of cells. Versatile biomaterials based on marine-origin macromolecules will be used, namely in the supramolecular assembly of instructive multilayers as nanostratified building-blocks for engineer such structures. The backbone of these biopolymers will be equipped with a variety of (bio)chemical elements permitting: post-processing chemistry and micro-patterning, specific/non-specific cell attachment, and cell-controlled degradation. Aiming at being applied in bone TE, ATLAS will integrate cells from different units of tissue physiology, namely bone and hematopoietic basic elements and consider the interactions between the immune and skeletal systems. These ingredients will permit to architect innovative films with high-level dialogue control with cells, but in particular sophisticated quasi-closed 3D capsules able to compartmentalise such components in a “globe-like” organization, providing local and long-range order for in vitro microtissue development and function. Such hybrid devices could be used in more generalised front-edge applications, including as disease models for drug discovery or test new therapies in vitro.
Max ERC Funding
2 498 988 €
Duration
Start date: 2015-12-01, End date: 2020-11-30
Project acronym BI-DSC
Project Building Integrated Dye Sensitized Solar Cells
Researcher (PI) Adélio Miguel Magalhaes Mendes
Host Institution (HI) UNIVERSIDADE DO PORTO
Call Details Advanced Grant (AdG), PE8, ERC-2012-ADG_20120216
Summary In the last decade, solar and photovoltaic (PV) technologies have emerged as a potentially major technology for power generation in the world. So far the PV field has been dominated by silicon devices, even though this technology is still expensive.Dye-sensitized solar cells (DSC) are an important type of thin-film photovoltaics due to their potential for low-cost fabrication and versatile applications, and because their aesthetic appearance, semi-transparency and different color possibilities.This advantageous characteristic makes DSC the first choice for building integrated photovoltaics.Despite their great potential, DSCs for building applications are still not available at commercial level. However, to bring DSCs to a marketable product several developments are still needed and the present project targets to give relevant answers to three key limitations: encapsulation, glass substrate enhanced electrical conductivity and more efficient and low-cost raw-materials. Recently, the proponent successfully addressed the hermetic devices sealing by developing a laser-assisted glass sealing procedure.Thus, BI-DSC proposal envisages the development of DSC modules 30x30cm2, containing four individual cells, and their incorporation in a 1m2 double glass sheet arrangement for BIPV with an energy efficiency of at least 9% and a lifetime of 20 years. Additionally, aiming at enhanced efficiency of the final device and decreased total costs of DSCs manufacturing, new materials will be also pursued. The following inner-components were identified as critical: carbon-based counter-electrode; carbon quantum-dots and hierarchically TiO2 photoelectrode. It is then clear that this project is divided into two research though parallel directions: a fundamental research line, contributing to the development of the new generation DSC technology; while a more applied research line targets the development of a DSC functional module that can be used to pave the way for its industrialization.
Summary
In the last decade, solar and photovoltaic (PV) technologies have emerged as a potentially major technology for power generation in the world. So far the PV field has been dominated by silicon devices, even though this technology is still expensive.Dye-sensitized solar cells (DSC) are an important type of thin-film photovoltaics due to their potential for low-cost fabrication and versatile applications, and because their aesthetic appearance, semi-transparency and different color possibilities.This advantageous characteristic makes DSC the first choice for building integrated photovoltaics.Despite their great potential, DSCs for building applications are still not available at commercial level. However, to bring DSCs to a marketable product several developments are still needed and the present project targets to give relevant answers to three key limitations: encapsulation, glass substrate enhanced electrical conductivity and more efficient and low-cost raw-materials. Recently, the proponent successfully addressed the hermetic devices sealing by developing a laser-assisted glass sealing procedure.Thus, BI-DSC proposal envisages the development of DSC modules 30x30cm2, containing four individual cells, and their incorporation in a 1m2 double glass sheet arrangement for BIPV with an energy efficiency of at least 9% and a lifetime of 20 years. Additionally, aiming at enhanced efficiency of the final device and decreased total costs of DSCs manufacturing, new materials will be also pursued. The following inner-components were identified as critical: carbon-based counter-electrode; carbon quantum-dots and hierarchically TiO2 photoelectrode. It is then clear that this project is divided into two research though parallel directions: a fundamental research line, contributing to the development of the new generation DSC technology; while a more applied research line targets the development of a DSC functional module that can be used to pave the way for its industrialization.
Max ERC Funding
1 989 300 €
Duration
Start date: 2013-03-01, End date: 2018-08-31
Project acronym BIC
Project Cavitation across scales: following Bubbles from Inception to Collapse
Researcher (PI) Carlo Massimo Casciola
Host Institution (HI) UNIVERSITA DEGLI STUDI DI ROMA LA SAPIENZA
Call Details Advanced Grant (AdG), PE8, ERC-2013-ADG
Summary Cavitation is the formation of vapor cavities inside a liquid due to low pressure. Cavitation is an ubiquitous and destructive phenomenon common to most engineering applications that deal with flowing water. At the same time, the extreme conditions realized in cavitation are increasingly exploited in medicine, chemistry, and biology. What makes cavitation unpredictable is its multiscale nature: nucleation of vapor bubbles heavily depends on micro- and nanoscale details; mesoscale phenomena, as bubble collapse, determine relevant macroscopic effects, e.g., cavitation damage. In addition, macroscopic flow conditions, such as turbulence, have a major impact on it.
The objective of the BIC project is to develop the lacking multiscale description of cavitation, by proposing new integrated numerical methods capable to perform quantitative predictions. The detailed and physically sound understanding of the multifaceted phenomena involved in cavitation (nucleation, bubble growth, transport, and collapse in turbulent flows) fostered by BIC project will result in new methods for designing fluid machinery, but also therapies in ultrasound medicine and chemical reactors. The BIC project builds upon the exceptionally broad experience of the PI and of his research group in numerical simulations of flows at different scales that include advanced atomistic simulations of nanoscale wetting phenomena, mesoscale models for multiphase flows, and particle-laden turbulent flows. The envisaged numerical methodologies (free-energy atomistic simulations, phase-field models, and Direct Numerical Simulation of bubble-laden flows) will be supported by targeted experimental activities, designed to validate models and characterize realistic conditions.
Summary
Cavitation is the formation of vapor cavities inside a liquid due to low pressure. Cavitation is an ubiquitous and destructive phenomenon common to most engineering applications that deal with flowing water. At the same time, the extreme conditions realized in cavitation are increasingly exploited in medicine, chemistry, and biology. What makes cavitation unpredictable is its multiscale nature: nucleation of vapor bubbles heavily depends on micro- and nanoscale details; mesoscale phenomena, as bubble collapse, determine relevant macroscopic effects, e.g., cavitation damage. In addition, macroscopic flow conditions, such as turbulence, have a major impact on it.
The objective of the BIC project is to develop the lacking multiscale description of cavitation, by proposing new integrated numerical methods capable to perform quantitative predictions. The detailed and physically sound understanding of the multifaceted phenomena involved in cavitation (nucleation, bubble growth, transport, and collapse in turbulent flows) fostered by BIC project will result in new methods for designing fluid machinery, but also therapies in ultrasound medicine and chemical reactors. The BIC project builds upon the exceptionally broad experience of the PI and of his research group in numerical simulations of flows at different scales that include advanced atomistic simulations of nanoscale wetting phenomena, mesoscale models for multiphase flows, and particle-laden turbulent flows. The envisaged numerical methodologies (free-energy atomistic simulations, phase-field models, and Direct Numerical Simulation of bubble-laden flows) will be supported by targeted experimental activities, designed to validate models and characterize realistic conditions.
Max ERC Funding
2 491 200 €
Duration
Start date: 2014-02-01, End date: 2019-01-31
Project acronym Bio-Plan
Project Bio-Inspired Microfluidics Platform for Biomechanical Analysis
Researcher (PI) Jacob Marinus Jan DEN TOONDER
Host Institution (HI) TECHNISCHE UNIVERSITEIT EINDHOVEN
Call Details Advanced Grant (AdG), PE8, ERC-2018-ADG
Summary Biomechanical interactions between cells and their environment are essential in almost any biological process, from embryonic development to organ function to diseases. Hence, biomechanical interactions are crucial for health and disease. Examples are hydrodynamic interactions through fluid flow, and forces acting directly on cells. Existing methods to analyze and understand these interactions are limited however, since they do not offer the required combination of precisely controlled flow and accurate applying and sensing of forces. Also, they often lack a physiological environment. A breakthrough in biomechanical analysis is therefore highly needed. We will realize a novel microfluidic platform for biomechanical analysis with unprecedented possibilities of controlling fluid flow and applying and sensing time-dependent forces at subcellular scales in controlled environments. The platform will be uniquely based on bio-inspired magnetic artificial cilia, rather than on conventional microfluidic valves and pumps. Cilia are microscopic hairs ubiquitously present in nature, acting both as actuators and sensors, essential for swimming of microorganisms, transport of dirt out of our airways, and sensing of sound, i.e. they exactly fulfill functions needed in biomechanical analysis. We will develop novel materials and fabrication methods to realize microscopic polymeric artificial cilia, and integrate these in microfluidic devices. Magnetic actuation and optical readout systems complete the platform. We will apply the novel platform to address three fundamental and unresolved biomechanical questions: 1. How do hydrodynamic interactions with actuated cilia steer cellular and particle transport? 2. How do local and dynamic mechanical forces on cells fundamentally influence their motility and differentiation? 3. How do hydrodynamic interactions between cilia steer embryonic development? This unique platform will enable to address many other future biomechanical questions.
Summary
Biomechanical interactions between cells and their environment are essential in almost any biological process, from embryonic development to organ function to diseases. Hence, biomechanical interactions are crucial for health and disease. Examples are hydrodynamic interactions through fluid flow, and forces acting directly on cells. Existing methods to analyze and understand these interactions are limited however, since they do not offer the required combination of precisely controlled flow and accurate applying and sensing of forces. Also, they often lack a physiological environment. A breakthrough in biomechanical analysis is therefore highly needed. We will realize a novel microfluidic platform for biomechanical analysis with unprecedented possibilities of controlling fluid flow and applying and sensing time-dependent forces at subcellular scales in controlled environments. The platform will be uniquely based on bio-inspired magnetic artificial cilia, rather than on conventional microfluidic valves and pumps. Cilia are microscopic hairs ubiquitously present in nature, acting both as actuators and sensors, essential for swimming of microorganisms, transport of dirt out of our airways, and sensing of sound, i.e. they exactly fulfill functions needed in biomechanical analysis. We will develop novel materials and fabrication methods to realize microscopic polymeric artificial cilia, and integrate these in microfluidic devices. Magnetic actuation and optical readout systems complete the platform. We will apply the novel platform to address three fundamental and unresolved biomechanical questions: 1. How do hydrodynamic interactions with actuated cilia steer cellular and particle transport? 2. How do local and dynamic mechanical forces on cells fundamentally influence their motility and differentiation? 3. How do hydrodynamic interactions between cilia steer embryonic development? This unique platform will enable to address many other future biomechanical questions.
Max ERC Funding
3 083 625 €
Duration
Start date: 2019-10-01, End date: 2024-09-30
Project acronym BioBlood
Project Development of a Bio-Inspired Blood Factory for Personalised Healthcare
Researcher (PI) Athanasios Mantalaris
Host Institution (HI) IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
Call Details Advanced Grant (AdG), PE8, ERC-2013-ADG
Summary Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information and/or application of patient-specific cell-based therapies. BioBlood aims to deliver personalised healthcare through a “step change” in the clinical field of haemato-oncology. BioBlood represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis that receives disease & patient input (patient primary cells & patient/disease-specific data) and will produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Blood supply to meet demand is the primary challenge for Blood Banks and requires significant resources to avoid shortages and ensure safety. An alternative, practical and cost-effective solution to conventional donated blood is essential to reduce patient morbidity and mortality, stabilise and guarantee the donor supply, limit multiple donor exposures, reduce risk of infection of known or as yet unidentified pathogens, and ensure a robust and safe turn-around for blood supply management. BioBlood aims to meet this challenge by developing a novel in vitro platform for the mass production of RBCs for clinical use. More than £32b/year is spent to develop and bring new drugs to market, which takes 14 years. Most patients diagnosed with leukaemias are unable to tolerate treatment and would benefit from novel agents. There is a need to optimise current treatment schedules for cancers such as AML to limit toxicities and improve clinical trial pathways for new drugs to enable personalised healthcare. BioBlood’s in vitro & in silico platform would be a powerful tool to tailor treatments in a patient- and leukaemia-specific chemotherapy schedule by considering the level of toxicity to the specific individual and treatment efficiency for the specific leukaemia a priori.
Summary
Personalized medicine is a medical model that proposes the customization of healthcare, with decisions and practices being tailored to the individual patient by use of patient-specific information and/or application of patient-specific cell-based therapies. BioBlood aims to deliver personalised healthcare through a “step change” in the clinical field of haemato-oncology. BioBlood represents an engineered bio-inspired integrated experimental/modelling platform for normal and abnormal haematopoiesis that receives disease & patient input (patient primary cells & patient/disease-specific data) and will produce cellular (red blood cell product) and drug (optimal drug treatment) therapies as its output. Blood supply to meet demand is the primary challenge for Blood Banks and requires significant resources to avoid shortages and ensure safety. An alternative, practical and cost-effective solution to conventional donated blood is essential to reduce patient morbidity and mortality, stabilise and guarantee the donor supply, limit multiple donor exposures, reduce risk of infection of known or as yet unidentified pathogens, and ensure a robust and safe turn-around for blood supply management. BioBlood aims to meet this challenge by developing a novel in vitro platform for the mass production of RBCs for clinical use. More than £32b/year is spent to develop and bring new drugs to market, which takes 14 years. Most patients diagnosed with leukaemias are unable to tolerate treatment and would benefit from novel agents. There is a need to optimise current treatment schedules for cancers such as AML to limit toxicities and improve clinical trial pathways for new drugs to enable personalised healthcare. BioBlood’s in vitro & in silico platform would be a powerful tool to tailor treatments in a patient- and leukaemia-specific chemotherapy schedule by considering the level of toxicity to the specific individual and treatment efficiency for the specific leukaemia a priori.
Max ERC Funding
2 498 903 €
Duration
Start date: 2014-01-01, End date: 2018-12-31
